William W Busse MD
Asthma & Allergic Conditions
Professor of Allergy & Immunology, University Wisc
Join to View Full Profile
5510 South Hill DrMadison, WI 53705
Phone+1 608-263-6180
Fax+1 608-263-9103
Are you Dr. Busse?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. William Busse, MD is an allergist/immunologist in Madison, Wisconsin. He is currently licensed to practice medicine in Wisconsin. He is a Professor of Allergy & Immunology at University Wisc.
Education & Training
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1970 - 1973- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1967 - 1968
University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1966 - 1967
University of Wisconsin School of Medicine & Public HealthClass of 1966- University of Wisconsin Hospitals and ClinicsResidency, Allergy and Immunology
Certifications & Licensure
WI State Medical License 1967 - 2021
American Board of Allergy and Immunology Allergy & Immunology
Publications & Presentations
PubMed
- Oncostatin-M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma.Stephane Esnault, Ksenija Bernau, Heather L Floerke, Arnaud Dendooven, Emeline Delaunay
Allergy. 2025-04-01 - The Direct and Indirect Role of IgE on Airway Epithelium in Asthma.Christian Domingo, William W Busse, Nicola A Hanania, Muyesser Ertugrul, Lauren A Millette
Allergy. 2025-04-01 - Regional brain structural alterations in reward and salience networks in asthma.Danielle Carrol, William W Busse, Corrina J Frye, Danika R Klaus, Julia C Bach
Brain, Behavior, and Immunity. 2025-02-05
Press Mentions
Antibody Treatment Reduces Asthma Attacks in Children Living in Disadvantaged Urban AreasAugust 17th, 2022- School Pest Management Program Significantly Reduced Asthma Symptoms in KidsSeptember 10th, 2021
FASENRA (Benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in Severe Eosinophilic AsthmaNovember 23rd, 2019- Join now to see all
